References
- Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840–50.
- Arbyn M, Castellsague X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22: 2675–82.
- Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24(Suppl. 3): S3/11–25.
- Hildesheim A, Hadjmichael O, Schwartz P, et al. Risk factors for rapid onset cervical cancer. Am J Obstet Gynecol 1999; 180:571–7.
- Liebrich C, Brummer O, Von WR, et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol 2009;30:45–8.
- Herfs M, Yamamoto Y, Laury A, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci USA 2012;109: 10516–21.
- Petry KU, Luyten A, Justus A, et al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84 – results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis 2013;13:135–46.
- Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100–10.
- Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377: 2085–92.
- Kocken M, Helmerhorst TJ, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12:441–50.
- Siebert U, Sroczynski G, Hillemanns P, et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 2006;16: 185–92.
- Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(Suppl. 5):F88–99.
- Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32.
- TOMBOLA group: Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. BMJ 2009;339:b2549. doi: 10.1136/bmj.b2549 Accessed 12 May 2014 from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718086/
- Moss EL, Arbyn M, Dollery E, et al. European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol 2013;170:255–8.
- Luyten A, Scherbring S, Reinecke-Luthge A, et al. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany – experience over 3 years. J Clin Virol 2009;46(Suppl. 3): S5–10.